Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1449 articles about Takeda
-
FDA Reviews Takeda Pharmaceutical Co. Ltd.'s Actos Over Bladder Cancer Link
9/20/2010
-
Takeda Pharmaceutical Co. Ltd. And Orexigen Therapeutics, Inc. Sign $1 Billion Obesity Pact
9/3/2010
-
Takeda Pharmaceuticals North America, Inc.'s Actos Has Same Heart Risks as GlaxoSmithKline's Avandia, Researchers Find
8/25/2010
-
Takeda Pharmaceutical Co. Ltd. Says Lifestyle-Disease Drugs Will Drive Growth
8/19/2010
-
R-Tech Ueno Submits Request for Arbitration Against Takeda Pharmaceutical Co. Ltd.
8/16/2010
-
Technology Vision Group Announces Leaders Are Looking for Deals at the 18th Annual B
8/12/2010
Technology Vision Group Announces Merck & Co., Inc., AstraZeneca PLC, Pfizer Inc., GlaxoSmithKline, Novartis Corporation, BMS Medical Imaging, Roche, Takeda Pharmaceutical Co. Ltd., Amgen, and Genzyme Corporation Are Looking for Deals at the 18th Annual B
-
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure
8/5/2010
-
Ariadne Genomics, Inc. Technology Licensed by Takeda San Francisco For Evaluation of Potential Antibody Targets
7/13/2010
-
Takeda Pharmaceutical Co. Ltd.'s Mepact Rejected by UK's National Institute for Clinical Excellence (NICE) on Bone Cancer Survival
7/9/2010
-
AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Announce Acceptance of Submission of Feraheme(R) Marketing Authorization Application to the European Medicines Evaluation Agency
6/29/2010
-
Takeda Pharmaceutical Co. Ltd. Paid American Manager $6.2 Million, Double CEO Hasegawa
6/25/2010
-
Takeda Pharmaceuticals North America, Inc.: ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
6/22/2010
-
Affymax, Inc. Receives $30 Million Milestone Payments from Takeda Pharmaceutical Co. Ltd. for Database Lock of Phase 3 Clinical Trials for Hematide(TM)/Peginesatide
6/22/2010
-
Furiex Pharmaceuticals, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Receives Pricing Approval of NESINA(R) (Alogliptin) in Japan; To Trigger $7.5 Million Payment To Furiex From Takeda
6/11/2010
-
Takeda Pharmaceutical Co. Ltd. to Cut 1900 Jobs, Mainly in US
5/12/2010
-
Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
5/10/2010
-
Takeda Pharmaceutical Co. Ltd.: Data Presented at DDW About Rebound Symptoms in Healed Erosive Esophagitis Patients After Completion of Treatment with DEXILANT(TM) (dexlansoprazole)
5/5/2010
-
Takeda Pharmaceuticals North America, Inc.: Pivotal Phase 3 Data Demonstrated Investigational Compound Azilsartan Medoxomil Lowered Blood Pressure in Head-to-Head Comparator Trials
5/3/2010
-
Takeda Pharmaceutical Co. Ltd. Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension
4/28/2010
-
PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Receives NDA Approval of NESINA(R) (Alogliptin) from Japanese Ministry of Health, Labour and Welfare
4/27/2010